Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 80

1 185 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 185
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 185 trials in Lyon

Open in trial search

Neoplasm malignant+1

Not recruiting

Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic obstructive pulmonary disease

Not recruiting

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Ovarian cancer stage III

Not recruiting

Study on the Effect of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Stage III Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Soft tissue sarcoma

Not recruiting

Study on the Effectiveness and Safety of L19TNF and Dacarbazine for Patients with Advanced or Metastatic Soft-Tissue Sarcoma After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Philogen S.p.A.

Leukaemia+1

Not recruiting

Study of dasatinib treatment in children and adolescents with Philadelphia chromosome-positive leukemia who cannot take imatinib or for whom imatinib is not effective

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dasatinib
  • Sponsor:Bristol Myers Squibb International Corporation

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Sepsis+1

Not recruiting

Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tin816
  • Sponsor:Novartis Pharma AG

Hidradenitis

Not recruiting

Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Chronic myeloid leukaemia

Not recruiting

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.